Glucosamine supplements may speed memory loss from Alzheimer’s: Study
A study links glucosamine—a common joint supplement—to accelerated cognitive decline and a 25% higher five-year mortality rate among Alzheimer’s patients. Researchers warn it may worsen brain glycosylation, a process linked to dementia. No regulatory guidance has been issued. New reports amplify concerns but do not add substantiated details.
What changed
Recent articles reiterate the study’s findings without introducing new data or expert commentary.
Live updates
-
Glucosamine supplements tied to faster Alzheimer’s decline, higher death risk in users
confidence 95%A study links glucosamine—a common joint supplement—to accelerated cognitive decline and a 25% higher five-year mortality rate among Alzheimer’s patients. Researchers warn it may worsen brain glycosylation, a process linked to dementia. No regulatory guidance has been issued. New reports amplify concerns but do not add substantiated details.
What's confirmed:
- Glucosamine supplements, widely used for joint pain, may accelerate Alzheimer’s progression and increase the five-year mortality rate by 25% in users.
- The supplement is linked to abnormal brain glycosylation, a process associated with dementia progression.
- Experts caution that glucosamine may harm brains already affected by Alzheimer’s while posing no clear risk to healthy individuals.
- No regulatory or consumer advisories have been issued regarding glucosamine use in relation to cognitive decline.
Still unconfirmed:
- A popular joint supplement was described as linked to 'frightening outcomes' in a new study (source: Yahoo Health).
- Researchers at the University of Florida suggest glucosamine may speed Alzheimer’s progression, though the study details are not provided in recent reports.
-
Glucosamine linked to faster Alzheimer’s memory loss and higher death risk in new study
confidence 92%A study published in *Nature Metabolism* finds glucosamine supplements—commonly used for joint pain—may accelerate cognitive decline in Alzheimer’s patients. Research shows a 25% higher five-year mortality rate among users and links glucosamine to abnormal brain glycosylation, a process tied to dementia progression. Experts warn the supplement may harm diseased brains while posing no clear risk to healthy ones. Regulatory or consumer guidance has not yet been issued.
What's confirmed:
- People with Alzheimer’s who took glucosamine were 25% more likely to die within five years than non-users, according to a *Nature Metabolism* study.
- Glucosamine worsens memory deficits in Alzheimer’s mouse models by fueling abnormal brain glycosylation, a metabolic driver of the disease.
- Reducing glycosylation in Alzheimer’s mice improved memory, while glucosamine supplementation was linked to poorer cognitive outcomes in human patients.
- The supplement appears safe for healthy brains but may accelerate decline in already diseased brains, per analysis of patient records and animal experiments.
Still unconfirmed:
- A single study suggests glucosamine may speed dementia progression beyond Alzheimer’s, though no additional sources confirm this claim.
- Regulatory agencies have not issued warnings or advisories regarding glucosamine use in Alzheimer’s patients as of June 16, 2026.